Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jan 13

PMID 33435539

Citations 13

Authors

Kazuhito Suzuki

Kaichi Nishiwaki

Shingo Yano

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is an uncurable hematological malignancy because of obtained drug resistance. Microenvironment and clonal evolution induce myeloma cells to develop de novo and acquired drug resistance, respectively. Cell adhesion-mediated drug resistance, which is induced by the interaction between myeloma and bone marrow stromal cells, and soluble factor-mediated drug resistance, which is induced by cytokines and growth factors, are two types of de novo drug resistance. The microenvironment, including conditions such as hypoxia, vascular and endosteal niches, contributes toward de novo drug resistance. Clonal evolution was associated with acquired drug resistance and classified as branching, linear, and neutral evolutions. The branching evolution is dependent on the microenvironment and escape of immunological surveillance while the linear and neutral evolution is independent of the microenvironment and associated with aggressive recurrence and poor prognosis. Proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibody agents (MoAbs), and autologous stem cell transplantation (ASCT) have improved prognosis of myeloma via improvement of the microenvironment. The initial treatment plays the most important role considering de novo and acquired drug resistance and should contain PIs, IMIDs, MoAb and ASCT. This review summarizes the role of anti-myeloma agents for microenvironment and clonal evolution and treatment strategies to overcome drug resistance.

Citing Articles

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.

Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L Mol Cancer. 2024; 23(1):88.

PMID: 38702734 PMC: 11067278. DOI: 10.1186/s12943-024-02005-y.

Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.

Hu Q, Wang M, Wang J, Tao Y, Niu T Oncol Res. 2024; 32(4):753-768.

PMID: 38560563 PMC: 10972724. DOI: 10.32604/or.2023.043647.

The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.

Bishop R, Miller A, Froid M, Nerlakanti N, Li T, Frieling J Nat Commun. 2024; 15(1):2458.

PMID: 38503736 PMC: 10951361. DOI: 10.1038/s41467-024-46594-0.

Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment.

Suzuki K, Yano S Cancers (Basel). 2023; 15(9).

PMID: 37173885 PMC: 10177433. DOI: 10.3390/cancers15092418.

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.

Plano F, Corsale A, Gigliotta E, Camarda G, Vullo C, Di Simone M Hematol Rep. 2023; 15(1):23-49.

PMID: 36648882 PMC: 9844382. DOI: 10.3390/hematolrep15010004.

References

Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y . Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther. 2009; 8(8):2329-38. DOI: 10.1158/1535-7163.MCT-09-0150. View

Alzrigat M, Jernberg-Wiklund H, Licht J . Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes. 2019; 2(3). PMC: 6370027. DOI: 10.3390/epigenomes2030016. View

Abroun S, Ishikawa H, Tsuyama N, Liu S, Li F, Otsuyama K . Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood. 2003; 103(6):2291-8. DOI: 10.1182/blood-2003-07-2187. View

Ogiya D, Liu J, Ohguchi H, Kurata K, Samur M, Tai Y . The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020; 136(20):2334-2345. PMC: 7702477. DOI: 10.1182/blood.2019004332. View

Arteche-Lopez A, Kreutzman A, Alegre A, Sanz Martin P, Aguado B, Gonzalez-Pardo M . Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. Bone Marrow Transplant. 2017; 52(6):832-838. DOI: 10.1038/bmt.2017.29. View

Paiva B, Cedena M, Puig N, Arana P, Vidriales M, Cordon L . Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016; 127(25):3165-74. DOI: 10.1182/blood-2016-03-705319. View

Jimenez-Zepeda V, Reece D, Trudel S, Chen C, Franke N, Winter A . Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. Leuk Lymphoma. 2015; 56(9):2668-73. DOI: 10.3109/10428194.2014.1003057. View

Qiang Y, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B . Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood. 2009; 113(18):4319-30. PMC: 2676089. DOI: 10.1182/blood-2008-08-174300. View

Sottoriva A, Kang H, Ma Z, Graham T, Salomon M, Zhao J . A Big Bang model of human colorectal tumor growth. Nat Genet. 2015; 47(3):209-16. PMC: 4575589. DOI: 10.1038/ng.3214. View

10.

Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F . A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003; 88(2):176-85. View

11.

Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L . Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009.... J Clin Oncol. 2017; 35(25):2911-2918. PMC: 5578392. DOI: 10.1200/JCO.2017.72.2975. View

12.

Lacy M, Alsina M, Fonseca R, Paccagnella M, Melvin C, Yin D . Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol. 2008; 26(19):3196-203. DOI: 10.1200/JCO.2007.15.9319. View

13.

Harrison J, Rameshwar P, Chang V, Bandari P . Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002; 99(1):394. DOI: 10.1182/blood.v99.1.394. View

14.

Kikuchi J, Koyama D, Mukai H, Furukawa Y . Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells. Int J Hematol. 2014; 99(6):726-36. DOI: 10.1007/s12185-014-1573-3. View

15.

Boulais P, Frenette P . Making sense of hematopoietic stem cell niches. Blood. 2015; 125(17):2621-9. PMC: 4408288. DOI: 10.1182/blood-2014-09-570192. View

16.

Galluzzo M, Pennacchietti S, Rosano S, Comoglio P, Michieli P . Prevention of hypoxia by myoglobin expression in human tumor cells promotes differentiation and inhibits metastasis. J Clin Invest. 2009; 119(4):865-75. PMC: 2662552. DOI: 10.1172/JCI36579. View

17.

Capp J, Bataille R . Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory. Cancers (Basel). 2020; 12(8). PMC: 7463431. DOI: 10.3390/cancers12082158. View

18.

Politou M, Heath D, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos M . Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006; 119(7):1728-31. DOI: 10.1002/ijc.22033. View

19.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

20.

Iyer S, Beck J, Stewart A, Shah J, Kelly K, Isaacs R . A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014; 167(3):366-75. DOI: 10.1111/bjh.13056. View